←
Valérie Fonteyne115 posts
Valérie Fonteyne avatar✓

Valérie Fonteyne ✓

@fontev1

Radiation-Oncologist, Ghent University Hospital, Belgium. Associate professor, Ghent University

◷ Joined February 2017▧ 4 Photos and videos
Dr Rishabh Jain avatar
⟳ Valérie Fonteyne retweeted
Dr Rishabh Jain@DrRishabhOnco·May 22

Adjuvant RT may finally be back in bladder cancer. The phase III BART trial shows that modern pelvic IMRT after cystectomy significantly improves locoregional control in high-risk MIBC. 🚨 🇮🇳 Multicenter randomized trial 153 patients 90% received perioperative chemotherapy 🩻 Adjuvant RT vs Observation after radical cystectomy 📌 2-year LRFS 87.1% vs 76.0% HR 0.43 (P=.04) 📌 2-year DFS 71.6% vs 58.7% 📌 2-year OS 70.4% vs 57.4% Most striking finding: ❌ No isolated pelvic recurrence after adjuvant RT. Despite historical concerns, toxicity remained low with modern IG-IMRT: ⚠️ Grade ≥3 acute toxicity: <5% ⚠️ No major increase in severe late toxicity This is important because pelvic failures after cystectomy are often devastating and rarely salvageable. The study strongly reopens the discussion around integrating pelvic RT into multimodality care for high-risk bladder cancer, especially in the modern immunotherapy era. Could adjuvant RT + IO become the next frontier in MIBC? 📖 Full paper in comment ⬇️ #OncoTwitter #MedTwitter #BladderCancer #RadOnc @ASCO @myesmo @esmo_o @OncoAlert

Post attachment
OncoAlert avatar
⟳ Valérie Fonteyne retweeted
OncoAlert@OncoAlert·5 Dec 2025

DEAR COLLEAGUES A reminder that #APCCC26 🇨🇭is coming in 2026 This is a Conference is OPEN TO EVERYONE, not just the Panel members and EARLY REGISTRATION is up until February 28, 2026 Awarm invite to the Advanced Prostate Cancer Consensus Conference #APCCC26 in Lugano🇨🇭 REGISTER HERE: apccc.org/apccc-2026/ Event Details: 📍 Palazzo Congressi, Lugano, Switzerland 🎟️ Register here 🎓 Credits requests: SGU – SSU, SSMO, SRO, SGMN In an era of rapid innovation and expanding treatment options for advanced #ProstateCancer , APCCC provides a vital forum for clinicians and researchers to address complex clinical questions where high-level evidence is limited. Over two days, the world’s leading experts will engage in high-level presentations, debates, and discussions to clarify and conceptualize the current landscape of care, with a focus on areas of controversy or uncertainty. The insights and consensus developed during the meeting are later published in European Urology, helping shape global standards. Creating new opportunities for younger investigators & the next generation of leaders in advanced prostate cancer! @Silke_Gillessen & @AOmlin @OncoAlert 🚨 @fabioturco92 @Prof_IanD #PROSCA25 @drjefstathiou @Prof_Nick_James @ChrisSweens1 @BertrandTOMBAL @ZilliThomas @neerajaiims @bjartell @PBlanchardMD @BourlonMaite @Albert0Briganti @cdanicas @Ecastromarcos @mdesantis234 @nachoduranm @drlouiseemmett @stefanofanti4 @fontev1 @Nicola_Fossati @marty_gleave @ProfKHerrmann @DrMHofman @BarbaraJereczek @ravikanesvaran @FacsRaja @LoebStacy @quimmateo @DrRanaMcKay @amerseburger @CaPsurvivorship @declangmurphy @DrPaulNguyen @WilliamOhMD @piet_ost @DrSpratticus @cnsternberg @DrYukselUrun @DrChoueiri @tompowles1 @brian_rini @nataliagandur

Post attachment
Valérie Fonteyne avatar
Valérie Fonteyne@fontev1·9 Oct 2025

Four years of hard work were rewarded yesterday with a wonderful PhD and PhD defence by @FlorVerghote ! The results of this research contribute to a better understanding of the role of radiotherapy in bladder cancer. Proud to have been your supervisor with @CharlesPraet !

Post attachment
Advanced Prostate Cancer Consensus Conference avatar
⟳ Valérie Fonteyne retweeted
Advanced Prostate Cancer Consensus Conference@APCCC_Lugano·11 Oct 2024

A great Pleasure to Present our paper on Management of patients with Advanced #ProstateCancer : A Report from #APCCC24 LINK TO ARTICLE👇👇👇👇👇👇👇👇 sciencedirect.com/science/ar… The 2024 Advanced Prostate Cancer Consensus Conference (APCCC) highlights significant advances in prostate cancer management while underscoring areas where high-quality evidence is still lacking. The conference gathered expert opinions on controversial clinical issues, particularly in advanced prostate cancer, offering guidance in cases where guidelines are unclear or conflicting. The report emphasizes personalized treatment approaches, considering patient-specific factors and evolving clinical data, and stresses the importance of ongoing clinical trials to fill knowledge gaps. It provides a practical framework for physicians and patients to engage in shared decision-making, especially in complex cases of high-risk localized and locally advanced prostate cancer. Our Thanks to all authors: @Silke_Gillessen @fabioturco92 @Prof_IanD @drjefstathiou Karim Fizazi @Prof_Nick_James Neal Shore Eric Small Matthew Smith @ChrisSweens1 @BertrandTOMBAL @ZilliThomas @neerajaiims Emmanuel S. Antonarakis Ana Aparicio Andrew J. Armstrong Diogo Assed Bastos Gerhardt Attard Karol Axcrona Mouna Ayadi Himisha Beltran @bjartell @PBlanchardMD @BourlonMaite @Albert0Briganti Muhammad Bulbul Consuelo Buttigliero Orazio Caffo @cdanicas @Ecastromarcos Heather H. Cheng Kim N. Chi Caroline S. Clarke Noel Clarke Johann S. de Bono @mdesantis234 @nachoduranm @EfstathiouEleni Onyeanunam N. Ekeke Tamer I.H. El Nahas @drlouiseemmett @stefanofanti4 Omolara A. Fatiregun Felix Y. Feng Peter C.C. Fong @fontev1 @Nicola_Fossati Daniel J. George @marty_gleave Gwenaelle Gravis Susan Halabi Daniel Heinrich @ProfKHerrmann @DrMHofman Thomas A. Hope Lisa G. Horvath Maha H.A. Hussain @BarbaraJereczek Robert J. Jones Anthony M. Joshua @ravikanesvaran Daniel Keizman @FacsRaja Gero Kramer @LoebStacy Brandon A. Mahal Fernando C. Maluf 75 76, @quimmateo David Matheson 78, Mika P. Matikainen 79, Ray McDermott 80, @DrRanaMcKay Niven Mehra 82, @amerseburger @CaPsurvivorship , Michael J. Morris 85, Hind Mrabti 86, Deborah Mukherji @declangmurphy Vedang Murthy Shingai B.A. Mutambirwa @DrPaulNguyen William K. Oh @piet_ost Joe M. O’Sullivan Anwar R. Padhani Chris Parker Darren M.C. Poon Colin C. Pritchard Danny M Rabah Dana Rathkopf Robert E. Reiter Raphaele Renard-Penna Charles J. Ryan Fred Saad Juan Pablo Sade Shahneen Sandhu Oliver A. Sartor Edward Schaeffer Howard I. Scher Nima Sharifi Iwona A. Skoneczna Howard R. Soule @DrSpratticus Sandy Srinivas @cnsternberg Hiroyoshi Suzuki Mary-Ellen Taplin Camilla Thellenberg-Karlsson Derya Tilki Levent N. Türkeri Hiroji Uemura @DrYukselUrun Claire L. Vale Neha Vapiwala Jochen Walz Kosj Yamoah Dingwei Ye Evan Y. Yu Almudena Zapatero @AOmlin

Post attachment
John Christodouleas avatar
⟳ Valérie Fonteyne retweeted
John Christodouleas@Xristodouleas·6 Oct 2024

We learned a lot about muscle-invasive bladder cancer this past week. Together, these studies suggest that a strategy worth exploring is to further de-intensify surgical lymph node management to reduce surgery-related mortality, while using adjuvant radiation to treat nodes in the ~30% of patients found to have pathologic T3-4 disease. 1. SWOG 1011 (Lerner SP et al NEJM 2024) shows that a more extensive pelvic LN dissection causes more harm than good, even in clinical T3-4 disease. (>10% of patients in extended lymphadenectomy group died within 6 months of randomization.) 2. SWOG 1011 suggest that if we could better manage pelvic LNs in pts with pathologic T3-T4 disease, we might improve cancer control. (HR~2, but we can’t know if a patient is pathologic T3-T4 till after radical cystectomy due to clinical-pathologic discordance problem.) 3. Marcq et al (JCO 2024) from McGill U. suggests that RT to pelvic LN is effective (in intact setting). (Multiple RCTs from Zaghloul M et al suggests RT effective in post-op setting too (most recent in IJROBP 2024)). 4. BART Trial (Murthy V et al ASTRO 2024) from Tata Memorial Hospital suggests that adjuvant radiation after radical cystectomy does not appear to meaningfully increase late toxicity. (Small bowel obstruction rates, our greatest worry, were similar with and without adjuvant RT.) @slernerbcmedu1 @siadaneshmand @VedangMurthy @docpriyamvada @BrianBaumannMD @TataMemorial @gautiermarcq @WesKassouf @SWOG @PaulSargos @fontev1 @NEJM @IJROBP

Post attachmentPost attachmentPost attachment